The Switch a GLP-1 Flips Inside the Beta Cell
The Switch a GLP-1 Flips Inside the Beta Cell
Salk researchers found one phosphate tag on one protein that turns on more than a thousand genes after a long exposure to a GLP-1 drug. It’s rat cells and mice, not people. Here’s what it shows, and what it doesn’t.
Give a beta cell a GLP-1 drug for one hour and 184 genes change. Leave the drug on for 16 hours and 1,065 genes change. That is the observation at the center of a study from the Salk Institute, published in PNAS in March 2026, and the team went looking for what makes the long exposure so different from the short one.
What they found is a switch. A protein called Med14, part of a large machine called Mediator that helps a cell read its genes, picks up a phosphate tag at one specific spot when the GLP-1 receptor is active. Tag on, and the beta cell reprograms itself: more activity at the insulin gene, faster fuel burning, a gene profile the authors compare to what they see in calorie-restricted mice. Tag blocked, and most of the long-exposure response disappears.
One thing before the details. Everything here was done in a rat beta-cell line and in mice. No human cells, no human islets, no patients. The study’s first author, Sam Van de Velde, told The Scientist it was “just one cell type.” Keep that in your pocket while you read.
Here is the chain, one step at a time.
What the study shows
Worth naming up front: the work was funded by the National Institutes of Health and by philanthropy, including Breakthrough T1D (the organization formerly called JDRF) and the Helmsley Charitable Trust. No drug company is listed as a funder of the study. The senior author is Marc Montminy, whose lab has spent decades on CREB, the well-known first responder in this pathway.
On the evidence ladder this is the bottom rung: mechanistic laboratory and animal research. That is not a knock. It is the kind of study that explains how something happens. It is not the kind that tells you whether a drug helps a person. Tap through where the evidence sits.
One wrinkle is worth pulling out of the evidence box because it changes how to picture the switch. Cells that could not tag Med14 did not simply go quiet. At rest, many of the genes a GLP-1 would normally turn on were already running higher than normal in the mutant cells, and the authors report that feedback signals which normally rein in cAMP were repressed. Their read is that the same phosphate site both turns the program on when the hormone is present and helps keep it in check when it isn’t. A switch, not just a gas pedal.
What nobody knows yet
The paper is candid about its edges. Two of them matter most for anyone reading this from outside a lab.
There is also a smaller, stranger limit. The team suspects the phosphate tag may change how Mediator gathers into little droplets inside the nucleus, which could explain why it favors cell-specific genes. They present that as a hypothesis, and it should be read as one.
One phosphate on one protein turned a short hormone signal into a long genomic program, in rat cells and in mice. The human chapter hasn’t been written.
Where this standsWhy this matters if you use insulin
The fair question from this audience is obvious: what does beta-cell resilience mean when type 1 has already taken most of your beta cells? Three things are worth knowing. First, a type 1 organization helped pay for this. Breakthrough T1D is a listed funder, and keeping beta cells alive under stress is a live question in type 1: at diagnosis, when some cells remain, and in cell-replacement therapies, where transplanted islets have to survive in a hostile environment. That connection is an editorial read, not the paper’s claim. The paper never mentions type 1.
Second, plenty of people with type 1 use a GLP-1 off-label, and this study does not move that decision in either direction. No GLP-1 is approved for type 1 diabetes as of this writing; phase 3 trials adding semaglutide to insulin therapy are registered and running on ClinicalTrials.gov. This work says nothing about safety, DKA risk, insulin needs, or dosing in a person. It says something about a protein in a dish.
Third, and this is the part that lingers: the whole finding is a timing story. Your own GLP-1 shows up at a meal and is gone in minutes, long before Med14 would ever get tagged. The drugs stick around for days, and in these experiments that staying power is what flipped the switch. The molecule was never the surprise. The duration was. If any of this bears on your care, bring it to a doctor who knows type 1 and knows you.
The study. Van de Velde S, Yu J, Evensen KG, Pakhlevanyan E, Williams AE, Shaw RJ, Montminy M. Med14 phosphorylation shapes genomic response to GLP-1 agonists. Proceedings of the National Academy of Sciences 123(10): e2536772123, published March 4, 2026 (PubMed PMC12974444). Funding listed: National Institutes of Health, Breakthrough T1D, Paul F. Glenn Foundation, Clayton Foundation, Leona M. and Harry B. Helmsley Charitable Trust. No industry funding listed. Evidence tier: mechanistic cell-line and mouse research.
Institutional release. Salk Institute, How do GLP-1 agonists affect gene expression?, March 5, 2026. Used for the funding statement and author affiliations.
The coverage. Roberts R. Prolonged GLP-1 Exposure Remodels Gene Expression in the Pancreas by Flipping a Molecular Switch, The Scientist, 2026. Used for the Van de Velde interview quotes.
Type 1 trial status. ClinicalTrials.gov phase 3 listings for semaglutide added to insulin in type 1 diabetes, for example NCT06894784 and NCT06082063, checked September 2026.
How to read this evidence. This is basic science: a rat insulinoma cell line (INS-1) and genetically modified mice, with the drug applied directly to cells or cultured islets. It shows a mechanism. It cannot show whether a GLP-1 helps, harms, or does nothing for any person, and it did not test human tissue. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved for type 2 diabetes and weight management; none is approved for type 1 diabetes.
This post is for educational purposes only and is not medical advice. Nothing here is a recommendation to start, stop, or change any medication. Talk with your doctor before making any changes to your care.
Listen to the Juicebox Podcast
Conversations about diabetes, five days a week, since 2015. Search “GLP-1” in the Juicebox FAQ for the episodes on off-label use in type 1.
Read the full disclaimer
